Allergic RhinitisNCT07079748
Study of the Effects and Mechanisms of Yeast Postbiotics on Persistent Allergic Rhinitis Symptoms
A study testing Yeast Postbiotics in people with Allergic Rhinitis, run by LanZhou University at 1 site in China.
Trial summary
This study is designed as a randomized, double-blind, placebo-controlled human intervention trial among university students with persistent allergic rhinitis (AR) symptoms. The aim is to evaluate the effectiveness of yeast postbiotics in alleviating persistent AR symptoms and to explore the potential mechanisms by… Read more about this study
- Who is it for?
- Ages 18 to 35 years
- Conditions the study is for
- Allergic Rhinitis
- What is being tested?
- Yeast Postbiotics
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 80 participants
- Where
- 1 siteChina
- Study dates
- 25 Jul 2025to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Aged between 18 and 35 years;
- Meeting the symptom criteria for persistent allergic rhinitis (AR) as defined in the Chinese Guidelines for Diagnosis and Treatment of Allergic Rhinitis (2022, Revised Edition): (1) Symptoms: Two or more of the following-paroxysmal sneezing, watery rhinorrhea, nasal itching, and nasal congestion-lasting continuously or cumulatively for at least 1 hour per day; ocular symptoms such as tearing, itching, and redness may also be present; (2) Persistent AR: Symptoms occur on ≥4 days per week and persist for ≥4 consecutive weeks;
- No use of probiotics, prebiotics, synbiotics, antihistamines, corticosteroids, or immunosuppressants within 1 month prior to screening;
- Willing and able to maintain usual physical activity levels and dietary patterns during the study;
- Able and willing to sign the informed consent form voluntarily.
Who cannot join
- Use of antibiotics, osmotic laxatives (e.g., magnesium sulfate, lactulose), anthraquinone-containing agents (e.g., rhubarb, aloe, senna), or gastrointestinal motility-promoting drugs (e.g., metoclopramide, domperidone, cisapride) within 1 month prior to screening;
- Diagnosed with non-allergic rhinitis (e.g., vasomotor rhinitis, infectious rhinitis, hormonal rhinitis, drug-induced rhinitis), or with nasal polyps, severe nasal septum deviation, cerebrospinal fluid rhinorrhea, or aspirin-exacerbated respiratory disease (AERD);
- Patients with uncontrolled allergic comorbidities, including sinusitis, otitis media, allergic asthma, or atopic dermatitis;
- History of serious gastrointestinal diseases (e.g., severe diarrhea, inflammatory bowel disease), or gastrointestinal endoscopy within the past month;
- Diagnosed with congenital genetic disorders, primary immunodeficiency diseases, severe systemic illnesses, or malignancies;
- Pregnant or lactating women, or women with plans to conceive during the study period.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
This study is designed as a randomized, double-blind, placebo-controlled human intervention trial among university students with persistent allergic rhinitis (AR) symptoms. The aim is to evaluate the effectiveness of yeast postbiotics in alleviating persistent AR symptoms and to explore the potential mechanisms by which yeast postbiotics modulate the gut microbiota to improve AR-related outcomes. A stratified randomization method will be applied to assign participants into the yeast postbiotic group and the placebo group. Stratification will be based on(1) Sex (male/female), and (2) Physician-diagnosed AR status (yes/no, based on self-reported clinical history), ensuring comparability between the two groups. During the intervention period, participants in the yeast postbiotic group will take two capsules of yeast postbiotic supplements daily after meals, while the placebo group will take two placebo capsules, identical in appearance and composition except without the active ingredients. The total study duration is 15 weeks, including a 1-week run-in period, 12-week intervention, and 2-week follow-up after the intervention.
All participants will be asked to complete a daily nasal symptom score (TNSS) and report any adverse events. At week 0, week 4, and week 12, follow-up assessments will be conducted, including: symptom and quality-of-life questionnaires (e.g., VAS, RQLQ), dietary intake surveys, anthropometric measurements (height, weight, body fat percentage), and biological sample collection (including blood, urine, saliva, and feces). Additionally, saliva samples will be collected specifically at week 2 of the intervention to assess mucosal immune markers.
Read the detailed description
Allergic rhinitis (AR) is a chronic, non-infectious inflammatory disease of the nasal mucosa mediated by immunoglobulin E (IgE) in atopic individuals after exposure to allergens. Typical clinical manifestations include paroxysmal sneezing, clear nasal discharge, nasal itching, and nasal congestion, often accompanied by itchy eyes, tearing, sleep disturbances, and decreased quality of life. AR is one of the most common chronic nasal diseases in clinical practice, affecting approximately 10%-20% of the global population, and has been recognized by the World Health Organization as a major public health issue.
This study is a randomized, double-blind, placebo-controlled human intervention trial among university students with persistent allergic rhinitis symptoms. It aims to evaluate the efficacy of yeast postbiotics in improving persistent AR symptoms and to explore the potential mechanisms through which yeast postbiotics may alleviate AR symptoms by modulating the gut microbiota. A total of 80 volunteers with persistent AR symptoms will be recruited and randomly assigned to the yeast postbiotic intervention group (n = 40) or the placebo group (n = 40). Both participants and investigators will be blinded to group allocation. The randomization information will only be accessible to the study designers, and all interventions and samples will be coded to prevent unblinding. If a participant experiences a serious adverse event due to the intervention, unblinding will be performed and the participant will be withdrawn from the study During the intervention period, participants in the intervention group will take two capsules of yeast postbiotics daily, each containing 250 mg of yeast postbiotics along with appropriate amounts of maltodextrin and silicon dioxide. The placebo group will take two capsules per day of an identically appearing placebo, which contains only maltodextrin and a small amount of silicon dioxide. All participants will take the capsules once daily after meals with warm water. All participants will complete a daily Total Nasal Symptom Score (TNSS) and report any adverse events. Follow-ups will be conducted at Week 0, Week 4, and Week 12, including questionnaire assessments (VAS, RQLQ), dietary surveys, anthropometric measurements (height, weight, body fat percentage), and biological sample collection (blood, urine, saliva, and stool). A saliva sample will also be collected at Week 2.
The primary outcome of this study is TNSS. Secondary outcomes include: Visual Analogue Scale (VAS), Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), Serum specific IgE (sIgE), Secretory IgA (sIgA), Inflammatory cytokines (IFN-γ, IL-4, IL-10, IL-6, and TNF-α), Gut microbiota composition, Serum biochemical indicators (CRP, ALT/AST, BUN/Cr). Statistical analysis will be conducted using SAS 9.4 software. Continuous variables will be expressed as mean ± standard deviation, and ordinal variables as proportions. T-tests and Kruskal-Wallis rank-sum tests will be used to compare continuous variables. Chi-square tests or Fisher's exact tests will be used for categorical variables. A p-value < 0.05 will be considered statistically significant. For outcome variables measured at multiple time points (e.g., VAS scores, cytokine levels at Weeks 0, 4, and 12), linear mixed-effects models (LMMs) will be constructed to assess the effects of time, group, and interaction, and to compare the trends across different time points between the intervention and control groups.
- Conditions
- Allergic Rhinitis
- Being tested
- Yeast Postbiotics, Placebo
- Keywords
- Allergic Rhinitis, Yeast Postbiotics
- Medical subject headings
- Rhinitis, Allergic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Yeast PostbioticsDietary supplement
Participants in the intervention group will take two capsules of yeast postbiotics daily after meals, with each capsule containing 250 mg of yeast postbiotics, along with maltodextrin and silicon dioxide.
PlaceboDietary supplement
Participants in the placebo group will take an equal number of placebo capsules, identical in dosage form, taste, appearance, and packaging. The placebo contains only maltodextrin and a small amount of silicon dioxide. All participants will take two capsules once daily, swallowed with warm water after meals.
| Study group | Role | What they receive |
|---|---|---|
| Yeast Postbiotic Group | Experimental | Participants in the intervention group will take two capsules of yeast postbiotics daily after meals, with each capsule containing 250 mg of yeast postbiotics, along with maltodextrin and silicon dioxide. Receives: Dietary Supplement: Yeast Postbiotics |
| Placebo Group | Placebo comparator | Participants in the placebo group will take an equal number of placebo capsules, identical in dosage form, taste, appearance, and packaging. The placebo contains only maltodextrin and a small amount of silicon dioxide. All participants will take two capsules once daily, swallowed with warm water after meals. Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total Nasal Symptom Score (TNSS)
A scoring system to evaluate the severity of four nasal symptoms: nasal itching, sneezing, rhinorrhea, and nasal congestion. Each symptom is rated on a scale of 0 to 3, with a total score ranging from 0 to 12. Higher scores indicate more severe symptoms.
Measured: Through intervention completion (Week 0 to Week 12)
Secondary outcomes (13)
Visual Analogue Scale (VAS)
A 10 cm straight-line scale where 0 represents "no symptoms" and 10 represents "worst imaginable symptoms." Participants mark a point on the line based on their subjective perception. It is used to evaluate the overall severity and frequency of allergic rhinitis (AR) symptoms.
Measured: Baseline week 4 week 12
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
A validated 28-item questionnaire covering seven domains: daily activities, sleep, nasal symptoms, ocular symptoms, emotional impact, practical problems, and environmental exposure. Each item is scored from 0 to 6; higher scores indicate greater impairment. Changes from baseline to post-intervention scores are used to evaluate improvements in quality of life.
Measured: Baseline week 4 week 12
Serum Specific IgE (sIgE)
Measured using Fluorescence Enzyme Immunoassay (FEIA), such as ImmunoCAP, to detect IgE antibodies specific to common allergens. A result ≥0.35 kU/L is considered positive, indicating sensitization. It reflects the individual's allergic status and changes over time.
Measured: Baseline week 4 week 12
Secretory IgA (sIgA)
Measured in fecal and saliva samples using ELISA kits. sIgA is an indicator of mucosal immune function and plays a role in first-line defense against pathogens.
Measured: Baseline week 2 week 4 week 12
IFN-γ
A signature cytokine of Th1-type immune responses, IFN-γ plays a critical role in activating macrophages, enhancing antigen presentation, and promoting cellular immunity. Fasting plasma levels of IFN-γ are measured using high-sensitivity ELISA kits.
Measured: Baseline week 4 week 12
IL-4
IL-4 is central in the pathogenesis of allergic diseases such as asthma and allergic rhinitis, contributing to eosinophilic infiltration and IgE production. Fasting plasma levels of IL-4 are measured using high-sensitivity ELISA kits.
Measured: Baseline week 4 week 12
IL-10
An anti-inflammatory cytokine that modulates immune responses by inhibiting the synthesis of pro-inflammatory cytokines. Fasting plasma levels of IL-10 are measured using high-sensitivity ELISA kits.
Measured: Baseline week 4 week 12
IL-6
A pleiotropic cytokine involved in both pro-inflammatory and anti-inflammatory processes. It plays a role in acute-phase responses, B-cell differentiation, and chronic inflammation. Fasting plasma levels of IL-6 are measured using high-sensitivity ELISA kits.
Measured: Baseline week 4 week 12
TNF-α
TNF-α is a central pro-inflammatory cytokine involved in the initiation and amplification of inflammation. It plays a major role in systemic inflammation and is implicated in numerous inflammatory and autoimmune conditions. Fasting plasma levels of TNF-α are measured using high-sensitivity ELISA kits.
Measured: Baseline week 4 week 12
C-reactive protein (CRP )
CRP is an acute-phase reactant produced by the liver in response to inflammation. Elevated CRP levels serve as a sensitive, though non-specific, marker of systemic inflammatory activity. CRP levels are measured using an automated biochemical analyzer.
Measured: Baseline week 4 week 12
ALT/AST
ALT and AST are hepatic enzymes that reflect liver function. Elevated levels are indicative of hepatocellular injury or inflammation. ALT/AST levels are measured using an automated biochemical analyzer.
Measured: Baseline week 4 week 12
BUN/Cr
BUN and creatinine are metabolic waste markers used to evaluate kidney function. Abnormal levels may indicate renal impairment. The BUN/Cr ratio is useful in distinguishing between prerenal and renal causes of dysfunction. BUN/Cr levels are measured using an automated biochemical analyzer.
Measured: Baseline week 4 week 12
Gut Microbiota Composition
Fecal microbiota is analyzed using 16S rRNA gene amplicon sequencing to evaluate microbial diversity (α/β diversity), relative abundance of dominant taxa, and ecological shifts in response to intervention.
Measured: Baseline week 4 week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jul 2025
- Study start25 Jul 2025 (estimated)
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Allergic RhinitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- LanZhou University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, lixiaoqin, LanZhou University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07079748
- Sponsor's protocol ID
- IRB25041501
- Status last verified
- Jul 2025
- First submitted
- 4 Jul 2025
- Last updated
- 23 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of the Effects and Mechanisms of Yeast Postbiotics on Persistent Allergic Rhinitis Symptoms
- ClinicalTrials.gov ID
- NCT07079748
- Acronym / sponsor ID
- IRB25041501
- Conditions
- Allergic Rhinitis
- Keywords
- Allergic Rhinitis, Yeast Postbiotics
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- LanZhou UniversityUniversity, hospital or other
- Study start
- 25 Jul 2025 (estimated)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 23 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is designed as a randomized, double-blind, placebo-controlled human intervention trial among university students with persistent allergic rhinitis (AR) symptoms. The aim is to evaluate the effectiveness of yeast postbiotics in alleviating persistent AR symptoms and to explore the potential mechanisms by which yeast postbiotics modulate the gut microbiota to improve AR-related outcomes. A stratified randomization method will be applied to assign participants into the yeast postbiotic group and the placebo group. Stratification will be based on(1) Sex (male/female), and (2) Physician-diagnosed AR status (yes/no, based on self-reported clinical history), ensuring comparability between the two groups. During the intervention period, participants in the yeast postbiotic group will take two capsules of yeast postbiotic supplements daily after meals, while the placebo group will take two placebo capsules, identical in appearance and composition except without the active ingredients. The total study duration is 15 weeks, including a 1-week run-in period, 12-week intervention, and 2-week follow-up after the intervention.
All participants will be asked to complete a daily nasal symptom score (TNSS) and report any adverse events. At week 0, week 4, and week 12, follow-up assessments will be conducted, including: symptom and quality-of-life questionnaires (e.g., VAS, RQLQ), dietary intake surveys, anthropometric measurements (height, weight, body fat percentage), and biological sample collection (including blood, urine, saliva, and feces). Additionally, saliva samples will be collected specifically at week 2 of the intervention to assess mucosal immune markers.
Detailed description
Allergic rhinitis (AR) is a chronic, non-infectious inflammatory disease of the nasal mucosa mediated by immunoglobulin E (IgE) in atopic individuals after exposure to allergens. Typical clinical manifestations include paroxysmal sneezing, clear nasal discharge, nasal itching, and nasal congestion, often accompanied by itchy eyes, tearing, sleep disturbances, and decreased quality of life. AR is one of the most common chronic nasal diseases in clinical practice, affecting approximately 10%-20% of the global population, and has been recognized by the World Health Organization as a major public health issue.
This study is a randomized, double-blind, placebo-controlled human intervention trial among university students with persistent allergic rhinitis symptoms. It aims to evaluate the efficacy of yeast postbiotics in improving persistent AR symptoms and to explore the potential mechanisms through which yeast postbiotics may alleviate AR symptoms by modulating the gut microbiota. A total of 80 volunteers with persistent AR symptoms will be recruited and randomly assigned to the yeast postbiotic intervention group (n = 40) or the placebo group (n = 40). Both participants and investigators will be blinded to group allocation. The randomization information will only be accessible to the study designers, and all interventions and samples will be coded to prevent unblinding. If a participant experiences a serious adverse event due to the intervention, unblinding will be performed and the participant will be withdrawn from the study During the intervention period, participants in the intervention group will take two capsules of yeast postbiotics daily, each containing 250 mg of yeast postbiotics along with appropriate amounts of maltodextrin and silicon dioxide. The placebo group will take two capsules per day of an identically appearing placebo, which contains only maltodextrin and a small amount of silicon dioxide. All participants will take the capsules once daily after meals with warm water. All participants will complete a daily Total Nasal Symptom Score (TNSS) and report any adverse events. Follow-ups will be conducted at Week 0, Week 4, and Week 12, including questionnaire assessments (VAS, RQLQ), dietary surveys, anthropometric measurements (height, weight, body fat percentage), and biological sample collection (blood, urine, saliva, and stool). A saliva sample will also be collected at Week 2.
The primary outcome of this study is TNSS. Secondary outcomes include: Visual Analogue Scale (VAS), Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), Serum specific IgE (sIgE), Secretory IgA (sIgA), Inflammatory cytokines (IFN-γ, IL-4, IL-10, IL-6, and TNF-α), Gut microbiota composition, Serum biochemical indicators (CRP, ALT/AST, BUN/Cr). Statistical analysis will be conducted using SAS 9.4 software. Continuous variables will be expressed as mean ± standard deviation, and ordinal variables as proportions. T-tests and Kruskal-Wallis rank-sum tests will be used to compare continuous variables. Chi-square tests or Fisher's exact tests will be used for categorical variables. A p-value < 0.05 will be considered statistically significant. For outcome variables measured at multiple time points (e.g., VAS scores, cytokine levels at Weeks 0, 4, and 12), linear mixed-effects models (LMMs) will be constructed to assess the effects of time, group, and interaction, and to compare the trends across different time points between the intervention and control groups.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Yeast Postbiotic Group | Experimental | Dietary Supplement: Yeast PostbioticsParticipants in the intervention group will take two capsules of yeast postbiotics daily after meals, with each capsule containing 250 mg of yeast postbiotics, along with maltodextrin and silicon dioxide. |
| Placebo Group | Placebo comparator | Dietary Supplement: PlaceboParticipants in the placebo group will take an equal number of placebo capsules, identical in dosage form, taste, appearance, and packaging. The placebo contains only maltodextrin and a small amount of silicon dioxide. All participants will take two capsules once daily, swallowed with warm water after meals. |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Aged between 18 and 35 years;
- Meeting the symptom criteria for persistent allergic rhinitis (AR) as defined in the Chinese Guidelines for Diagnosis and Treatment of Allergic Rhinitis (2022, Revised Edition): (1) Symptoms: Two or more of the following-paroxysmal sneezing, watery rhinorrhea, nasal itching, and nasal congestion-lasting continuously or cumulatively for at least 1 hour per day; ocular symptoms such as tearing, itching, and redness may also be present; (2) Persistent AR: Symptoms occur on ≥4 days per week and persist for ≥4 consecutive weeks;
- No use of probiotics, prebiotics, synbiotics, antihistamines, corticosteroids, or immunosuppressants within 1 month prior to screening;
- Willing and able to maintain usual physical activity levels and dietary patterns during the study;
- Able and willing to sign the informed consent form voluntarily.
Key exclusion criteria (6 listed)
- Use of antibiotics, osmotic laxatives (e.g., magnesium sulfate, lactulose), anthraquinone-containing agents (e.g., rhubarb, aloe, senna), or gastrointestinal motility-promoting drugs (e.g., metoclopramide, domperidone, cisapride) within 1 month prior to screening;
- Diagnosed with non-allergic rhinitis (e.g., vasomotor rhinitis, infectious rhinitis, hormonal rhinitis, drug-induced rhinitis), or with nasal polyps, severe nasal septum deviation, cerebrospinal fluid rhinorrhea, or aspirin-exacerbated respiratory disease (AERD);
- Patients with uncontrolled allergic comorbidities, including sinusitis, otitis media, allergic asthma, or atopic dermatitis;
- History of serious gastrointestinal diseases (e.g., severe diarrhea, inflammatory bowel disease), or gastrointestinal endoscopy within the past month;
- Diagnosed with congenital genetic disorders, primary immunodeficiency diseases, severe systemic illnesses, or malignancies;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Yeast PostbioticsParticipants in the intervention group will take two capsules of yeast postbiotics daily after meals, with each capsule containing 250 mg of yeast postbiotics, along with maltodextrin and silicon dioxide. | Dietary supplement | Yeast Postbiotic Group |
| PlaceboParticipants in the placebo group will take an equal number of placebo capsules, identical in dosage form, taste, appearance, and packaging. The placebo contains only maltodextrin and a small amount of silicon dioxide. All participants will take two capsules once daily, swallowed with warm water after meals. | Dietary supplement | Placebo Group |
Primary outcome
Total Nasal Symptom Score (TNSS)
Time frame: Through intervention completion (Week 0 to Week 12)
A scoring system to evaluate the severity of four nasal symptoms: nasal itching, sneezing, rhinorrhea, and nasal congestion. Each symptom is rated on a scale of 0 to 3, with a total score ranging from 0 to 12. Higher scores indicate more severe symptoms.
13 secondary outcomes
Visual Analogue Scale (VAS)
Time frame: Baseline week 4 week 12
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
Time frame: Baseline week 4 week 12
Serum Specific IgE (sIgE)
Time frame: Baseline week 4 week 12
Secretory IgA (sIgA)
Time frame: Baseline week 2 week 4 week 12
IFN-γ
Time frame: Baseline week 4 week 12
IL-4
Time frame: Baseline week 4 week 12
IL-10
Time frame: Baseline week 4 week 12
IL-6
Time frame: Baseline week 4 week 12
TNF-α
Time frame: Baseline week 4 week 12
C-reactive protein (CRP )
Time frame: Baseline week 4 week 12
ALT/AST
Time frame: Baseline week 4 week 12
BUN/Cr
Time frame: Baseline week 4 week 12
Gut Microbiota Composition
Time frame: Baseline week 4 week 12
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jul 2025.
- Individual participant dataSharing planned: No
Related trials for Allergic Rhinitis
Not yet recruitingPhase 1
Safety and Tolerability of Fluticasone Propionate 10% Nasal Insert in Participants With Chronic Allergic Rhinitis
Chronic Allergic Rhinitis
RecruitingPhase 3
Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis_MM09-SIT-063.
Allergic Rhinitis, Allergic Rhinoconjunctivitis
RecruitingPhase 3
Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis. MM09-SIT-063.
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Enrolling by invitationObservational study
Allergy, Asthma, and Atopic Eczema in Finland
Asthma, Asthma in Children
Not yet recruitingObservational study
Prevelance of Bronchial Asthma and Allergic Rhinitis Among Children With Nephrotic Syndrom at Sohag University Hospital
Allergic Diseases in Nephrotic Children, Nephrotic Syndrom
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Yeast Postbiotics in people with Allergic Rhinitis, run by LanZhou University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 23 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xiaoqin Li, Dr.Prof. (+86 15927366423, lixiaoqin@lzu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total Nasal Symptom Score (TNSS) (time frame: Through intervention completion (Week 0 to Week 12)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2025.